Patients with HR-positive/HER2-negative metastatic breast cancer (mBC) who receive antibody-drug conjugates (ADCs) have a unique spectrum of adverse events (AEs) that can lower quality of life (QoL). Patients and caregivers rely on health care providers for…
The rapid evolution of the HR-positive/HER2-negative treatment landscape has led to multiple revisions of clinical practice guidelines. Health care practitioners are challenged to consider the most current data while fine-tuning therapy selections, but also to incorporate…
The HR-positive/HER2-negative treatment landscape is rapidly evolving with the introduction of novel antibody-drug conjugate (ADC) therapies for patients who have developed resistance to endocrine-based therapy. This shifting paradigm effectuates uncertainty for health care practitioners regarding ADC…
Patient prognosis for endometrial cancer (EC) is highly benefited by molecular profiling, and national and international guidelines robustly recommend its integration into practice. Characterization of DNA mismatch repair (MMR) status identifies clinically significant molecular subtypes. This…
Patients with triple negative and HR-positive/HER2-negative breast cancer have limited treatment options after the development of endocrine resistance. This dearth of options is particularly acute for Black women and other marginalized patients, and results in treatment…
Patients with triple-negative breast cancer (TNBC), and those with HR-positive/HER2-negative breast cancer after the development of endocrine resistance, have limited treatment options. Black women are diagnosed more often with TNBC and feel the lack of treatment…
Reducing barriers to adequate anticoagulation for patients with cancer improves outcomes for those with cancer-associated venous thromboembolisms (CA-VTEs). Advances in cancer treatments and the resulting improvements in patient survival have led to an increase in the…